Clinical Trials on Cystic Fibrosis Related Diabetes in Russian Federation

Total 410 results

Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Mexico, Netherlands, Russian Federation, India, Belgium, Japan, Romania, Italy
Hoffmann-La Roche

Completed

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

Diabetes Mellitus Type 2

United States, Russian Federation, Israel, Mexico, Ukraine, Romania
Eli Lilly and Company

Withdrawn

A Study in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Spain, Poland, Austria, Germany, Czech Republic, Russian Federation
AstraZeneca
Quintiles, Inc.

Completed

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Type 2 Diabetes

United States, Korea, Republic of, India, Russian Federation, Brazil, Mexico, South Africa, Philippines
Chromaderm, Inc.

Completed

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Diabetic Retinopathy

United States, Canada, France, Denmark, Australia, Netherlands, Taiwan, Spain, Italy, Germany, Portugal, United Kingdom, Russian Federation, Poland, India, Brazil, Mexico
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Patients With Type 2 Diabetes

Diabetes Mellitus Type 2

Italy, Hong Kong, Romania, Greece, United States, Mexico, Serbia, Russian Federation
Lexicon Pharmaceuticals
Sanofi

Terminated

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE)

Type 2 Diabetes Mellitus

United States, Australia, Canada, Korea, Republic of, Mexico, New Zealand, Russian Federation, Taiwan
Novo Nordisk A/S

Completed

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Russian Federation, Serbia, Turkey, Algeria, Czechia
Novo Nordisk A/S

Completed

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Argentina, Slovakia, Greece, South Africa, Australia
Mannkind Corporation

Terminated

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Type 2 Diabetes Mellitus | Asthma | Type 1 Diabetes Mellitus | Moderate Chronic Obstructive Pulmonary Disease

United States, Russian Federation, Ukraine
Phenomix
Forest Laboratories

Terminated

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

Type 2 Diabetes Mellitus | Renal Impairment

United States, Russian Federation, Ukraine
AstraZeneca

Completed

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico, Mexico, Russian Federation, Romania, Poland, Czech Republic, United Kingdom
Boehringer Ingelheim

Completed

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Diabetes Mellitus, Type 2

United States, Argentina, Hungary, India, Japan, Poland, Russian Federation
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Diabetes Mellitus Type 2

Australia, Mexico, Taiwan, United States, Israel, Russian Federation, Slovakia, Ukraine, Guatemala, Peru, Romania
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus (ELEMENT 5)

Diabetes Mellitus, Type 2

India, Turkey, United States, Puerto Rico, Taiwan, Korea, Republic of, Russian Federation
Sanofi
Population Health Research Institute

Completed

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Diabetes Mellitus, Non-Insulin-Dependent

United States, France, Brazil, Poland, Romania, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, India, Philippines, Russian Federation, Slovakia, Mexico, Argentina, Croatia, Austria, Denmark, Finland, Hungary, Lithuania, Norw... and more
AstraZeneca

Completed

Faslodex in McCune-Albright Syndrome (FMAS)

Puberty, Precocious | McCune-Albright Syndrome

Italy, United States, Germany, France, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan (STEADFAST)

Type 2 Diabetes Mellitus

Egypt, United Kingdom, Turkey, Lebanon, Russian Federation, Tunisia, Malaysia, Germany, Spain, Saudi Arabia, Denmark, Indonesia, Jordan, Kuwait, Singapore, United Arab Emirates
ActivX Biosciences, Inc.
Kyorin Pharmaceutical Co.,Ltd

Completed

Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone (Synergy104)

Type 2 Diabetes

United States, Poland, Argentina, Russian Federation, Czech Republic, South Africa, Guatemala
Novo Nordisk A/S

Completed

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, United Kingdom, Denmark, Netherlands, Norway, South Africa, Finland, France, Spain, Former Serbia and Montenegro, Sweden
Hoffmann-La Roche

Completed

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Diabetes Mellitus Type 2

Australia, Hong Kong, Romania, United States, Japan, Russian Federation, Spain, Canada, Germany, Latvia, Mexico, Brazil
Sanofi

Completed

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany, Spain, United States, Canada, Czechia, Hungary, Mexico, Russian Federation
Sanofi

Completed

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes (PRESCHOOL)

Type 1 Diabetes Mellitus

United States, Austria, Brazil, Chile, Czech Republic, Germany, Hungary, India, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Turkey
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

India, Israel, Russian Federation, United Kingdom, Taiwan, Argentina, Finland, Hungary, Macedonia, The Former Yugoslav Republic of, Malaysia, Mexico, Norway, Serbia, South Africa
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

Diabetic Kidney Disease

Belgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more
AstraZeneca
Bristol-Myers Squibb

Completed

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Canada, Mexico, India, Puerto Rico, Russian Federation, South Africa
Sanofi

Terminated

Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)

Sleep Initiation and Maintenance Disorders

United States, Canada, Brazil, Russian Federation, Australia, Germany, Italy, Spain, Turkey, India, Malaysia, Singapore, Belgium, Czech Republic, Mexico, Argentina, Austria, Colombia, Chile, South Africa, United Kingdom, Hong Kong
AstraZeneca

Completed

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation, Romania, Poland, Czech Republic, Puerto Rico, Hungary
Sanofi

Completed

Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH Safety)

Hyponatremia | Inappropriate ADH Syndrome

United States, France, Brazil, Russian Federation, Australia, Germany, Switzerland, Belgium, Hungary, Hong Kong, Canada
Andromeda Biotech Ltd.

Completed

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults (DIA-AID2)

Type 1 Diabetes Mellitus

United States, Russian Federation, Israel, Spain, Lithuania, Germany, Austria, Belarus, Canada, Czech Republic, Finland, Hungary, Italy, Poland
Boehringer Ingelheim

Completed

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Argentina, Croatia, Estonia, Germany, Italy, Korea, Republic of, Lithuania, Romania, Russian Federation, Slovakia, Sweden, Taiwan, Ukraine
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

Diabetes Mellitus, Type 2 | Diabetic Nephropathy

United States, Canada, France, Germany, Poland, Ukraine, United Kingdom, China, Taiwan, Spain, Argentina, Colombia, Mexico, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Japan, Australia, Korea, Republic of, Chile, New Zealand and more
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, Austria, Japan, Norway, Puerto Rico
AstraZeneca

Completed

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes

United States, United Kingdom, Germany, Hungary, Mexico, Poland, Russian Federation, Romania, Czechia, Sweden
AstraZeneca
Eli Lilly and Company

Completed

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Type 2 Diabetes Mellitus

United States, Czech Republic, France, Korea, Republic of, Russian Federation, Spain, Mexico, Australia, Belgium, Denmark, Germany, Hungary, Netherlands, Puerto Rico, Greece, Taiwan
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation
Sanofi

Completed

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Type 2 Diabetes Mellitus

Spain, United States, Canada, Czech Republic, France, Germany, Poland, Romania, Russian Federation, Ukraine
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms (DUAL™ VI)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Canada, Austria, Hungary, Serbia, Russian Federation, Bulgaria, Czechia
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Diabetes Mellitus Type 2

Australia, Hong Kong, Colombia, Russian Federation, Germany, Hungary, Italy, Mexico, Peru, Romania, Slovakia, Brazil, El Salvador
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of
AstraZeneca

Completed

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (MEASURE-HF)

Heart Failure | Type 2 Diabetes Mellitus

United States, Thailand, Korea, Republic of, Russian Federation, Ukraine, Hungary, Bulgaria, Chile, Canada, Romania
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Diabetes Mellitus, Type 2

United States, Romania, Canada, Russian Federation, Czech Republic, Slovakia, Mexico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Nutritional and Metabolic Diseases

United Kingdom, Germany, Belgium, Poland, India, Finland, Sweden, Netherlands, Russian Federation, Norway, Denmark
Bayer

Completed

Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

Diabetic Foot | Ulcer | Abscess | Wound Infection

Italy, Spain, Greece, Ireland, Russian Federation, United Kingdom, Germany, Austria, Belgium, France, Hungary, South Africa, Romania, Bulgaria, Poland, Israel, Latvia, Ukraine, Lithuania, Netherlands
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Croatia, Italy, Slovakia, Denmark, Macedonia, The Former Yugoslav Republic of, Norway, Russian Federation, Finland, France, Poland, Greece, Romania, Sweden, Czech Republic, Argentina
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

Diabetes Mellitus

China, United States, Canada, Mexico, Russian Federation, Croatia, United Kingdom, Argentina, Australia, India, South Africa, Greece, Ukraine, Romania, Italy, Hong Kong, Former Serbia and Montenegro, Brazil
Eli Lilly and Company

Completed

A Study in Participants With Type 1 Diabetes Mellitus (IMAGINE 1)

Diabetes Mellitus, Type 1

Japan, United States, Russian Federation, France, Mexico, Austria, Germany, Italy, Poland
Novo Nordisk A/S

Completed

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Russian Federation, Puerto Rico, United Arab Emirates, Brazil
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Slovakia, Greece, Argentina, South Africa, Australia

Clinical Trials on Cystic Fibrosis Related Diabetes in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations